In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer

Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in EOC lead to PARP inhibitor resistance and reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Z. Ping, Al Zouabi, Nour N., Xu, Mark L., Bowen, Nicole E., Wu, Terence L., Lavi, Ethan S., Huang, Pamela H., Zhu, Yong-Lian, Kim, Baek, Ratner, Elena S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044145/
https://www.ncbi.nlm.nih.gov/pubmed/33850183
http://dx.doi.org/10.1038/s41598-021-87325-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044145/
https://www.ncbi.nlm.nih.gov/pubmed/33850183
http://dx.doi.org/10.1038/s41598-021-87325-5

Ejemplares similares